Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 2.75M
Average 3.67M
TNGX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Tango Therapeutics, Inc.NASDAQ: TNGX
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $24.91M rose 275.9% year over year, ahead of the +109.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 47.4% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Stock-based compensation amounted to 42.4% of revenue in FY2025, down 26.3 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +275.9% holds above the trailing-twelve-month pace of +109.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 26.43M USD
- Year-over-year change
- -8.5%
- 4-year CAGR
- +35.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.43M | -8.5% |
| FY2024 | 2024-12-31 | 28.9M | +51.5% |
| FY2023 | 2023-12-31 | 19.08M | +34.1% |
| FY2022 | 2022-12-31 | 14.23M | +81.7% |
| FY2021 | 2021-12-31 | 7.83M | — |
Stock-Based Compensation vs competitors
How TNGX compares with its peers on the latest reported figures
- TNGX's LTM Sep 2026 stock-based compensation of $58.58M is the 2nd largest of the 11 companies compared; the peer median is $26.04M.
- Its year-over-year change of +109.9% is the highest of 11, against a peer median of -1.1%.
- Over three fiscal years its annual growth of +22.9% compares with a peer median of +10.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $151.77M | +56.3% | +56.0% | — | |
| LTM Sep 2026 | $58.58M | +109.9% | +22.9% | — | |
| LTM Mar 2026 | $50.41M | +30.4% | +58.3% | 22.4% | |
| LTM Jun 2026 | $48.31M | -34.7% | +3.6% | 466.8% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Sep 2026 | $35.82M | +41.1% | +7.4% | — | |
| LTM Jun 2026 | $19.89M | -153.0% | +30.1% | 11.7% | |
| LTM Mar 2026 | $16.26M | -43.8% | -14.0% | 46.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $13.11M | -11.0% | +88.9% | — |
| LTM Mar 2026 | $10.08M | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| Peer median (excluding TNGX) | $26.04M | -1.1% | +10.5% | 26.1% | |
Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.24M) | (108.18M) | (101.74M) | (130.3M) | (101.59M) |
| Depreciation & Amortization | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.83M | 14.23M | 19.08M | 28.9M | 26.43M |
| Change in Working Capital | (11.35M) | (18.49M) | (37.97M) | (31.75M) | (67.2M) |
| Accounts Receivables | 0 | 0 | 2M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.23M | 1.1M | (1.71M) | (1.18M) | (825K) |
| Other Working Capital | (12.58M) | (19.59M) | (38.26M) | (30.56M) | (66.37M) |
| Other Non-Cash Items | 1.32M | 1.75M | 234K | (849K) | 1.2M |
| Operating Cash Flow | (59.53M) | (109.08M) | (117.98M) | (131.5M) | (138.89M) |
| Capital Expenditures | (1.84M) | (7.69M) | (1.53M) | (754K) | (1.05M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (372.36M) | (208.5M) | (310.57M) | (240.89M) | (264.46M) |
| Sales of Investments | 190.76M | 242.6M | 353.53M | 327.77M | 224.64M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (183.43M) | 26.4M | 41.43M | 86.13M | (40.87M) |
| Debt Repayment | 342.11M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 80.02M | 41.72M | 222.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.78M) | 1.62M | 2.39M | 5.94M | (36K) |
| Financing Cash Flow | 357.33M | 1.62M | 82.41M | 47.66M | 222.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 114.36M | (81.07M) | 5.85M | 2.29M | 42.75M |
| Free Cash Flow | (61.36M) | (116.77M) | (119.51M) | (132.26M) | (139.93M) |
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$21.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.